Literature DB >> 2539491

Mapping of attenuating sequences of an avirulent poliovirus type 2 strain.

E G Moss1, R E O'Neill, V R Racaniello.   

Abstract

A mouse model for poliomyelitis was used to identify genomic sequences that attenuate neurovirulence of poliovirus strain P2/P712. This type 2 strain is avirulent in primates and mice yet grows as well as virulent strains in cell culture. The approach used was to exchange portions of the genome of the mouse-virulent P2/Lansing strain with the corresponding region from P2/P712 to identify sequences that could attenuate Lansing neurovirulence in mice. A full-length infectious cDNA of P2/P712 was assembled and used to construct recombinants between P2/P712 and P2/Lansing. The results of neurovirulence testing of 11 recombinants indicated that strong attenuating determinants are located in the 5' noncoding region of P2/P712 and a region encoding capsid protein VP1 and 2Apro, 2B, and part of 2C. An attenuating determinant was further localized to between nucleotides 456 and 628 of P2/P712. A third sequence from P2/P712, nucleotides 752 to 2268, encoding VP4, VP2, and part of VP3, was weakly attenuating. The sequence from nucleotide 4454, approximately halfway through the 2C-coding region, to the end of the P2/P712 genome did not contain attenuating determinants. Nucleotide sequence analysis revealed that P2/P712 differs from the type 2 Sabin vaccine strain by only 22 nucleotides. Six differences lead to amino acid changes in the coding region, and four differences are in the 5' noncoding region. These studies show that, like the type 1 and type 3 Sabin vaccine strains, the attenuated type 2 strain P712 contains multiple attenuating sequences, including strongly attenuating sequences in the 5' noncoding region of the genome.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2539491      PMCID: PMC250599     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  26 in total

1.  Present status of attenuated live-virus poliomyelitis vaccine.

Authors:  A B SABIN
Journal:  J Am Med Assoc       Date:  1956-12-29

2.  In vitro phenotypic markers of a poliovirus recombinant constructed from infectious cDNA clones of the neurovirulent Mahoney strain and the attenuated Sabin 1 strain.

Authors:  M Kohara; T Omata; A Kameda; B L Semler; H Itoh; E Wimmer; A Nomoto
Journal:  J Virol       Date:  1985-03       Impact factor: 5.103

3.  Preparative and analytical purification of DNA from agarose.

Authors:  B Vogelstein; D Gillespie
Journal:  Proc Natl Acad Sci U S A       Date:  1979-02       Impact factor: 11.205

4.  Reversion to neurovirulence of the live-attenuated Sabin type 3 oral poliovirus vaccine.

Authors:  A J Cann; G Stanway; P J Hughes; P D Minor; D M Evans; G C Schild; J W Almond
Journal:  Nucleic Acids Res       Date:  1984-10-25       Impact factor: 16.971

5.  Molecular cloning of poliovirus cDNA and determination of the complete nucleotide sequence of the viral genome.

Authors:  V R Racaniello; D Baltimore
Journal:  Proc Natl Acad Sci U S A       Date:  1981-08       Impact factor: 11.205

6.  Cloned poliovirus complementary DNA is infectious in mammalian cells.

Authors:  V R Racaniello; D Baltimore
Journal:  Science       Date:  1981-11-20       Impact factor: 47.728

7.  The pUC plasmids, an M13mp7-derived system for insertion mutagenesis and sequencing with synthetic universal primers.

Authors:  J Vieira; J Messing
Journal:  Gene       Date:  1982-10       Impact factor: 3.688

8.  Pathogenesis of human poliovirus infection in mice. I. Clinical and pathological studies.

Authors:  B Jubelt; G Gallez-Hawkins; O Narayan; R T Johnson
Journal:  J Neuropathol Exp Neurol       Date:  1980-03       Impact factor: 3.685

9.  Studies on transformation of Escherichia coli with plasmids.

Authors:  D Hanahan
Journal:  J Mol Biol       Date:  1983-06-05       Impact factor: 5.469

10.  Molecular cloning and characterization of hepatitis A virus cDNA.

Authors:  J R Ticehurst; V R Racaniello; B M Baroudy; D Baltimore; R H Purcell; S M Feinstone
Journal:  Proc Natl Acad Sci U S A       Date:  1983-10       Impact factor: 11.205

View more
  33 in total

1.  Structure and function analysis of the poliovirus cis-acting replication element (CRE).

Authors:  Ian G Goodfellow; David Kerrigan; David J Evans
Journal:  RNA       Date:  2003-01       Impact factor: 4.942

2.  A mutation present in the amino terminus of Sabin 3 poliovirus VP1 protein is attenuating.

Authors:  J M Tatem; C Weeks-Levy; A Georgiu; S J DiMichele; E J Gorgacz; V R Racaniello; F R Cano; S J Mento
Journal:  J Virol       Date:  1992-05       Impact factor: 5.103

Review 3.  Foot-and-mouth disease.

Authors:  Marvin J Grubman; Barry Baxt
Journal:  Clin Microbiol Rev       Date:  2004-04       Impact factor: 26.132

4.  Quantitation of relative fitness and great adaptability of clonal populations of RNA viruses.

Authors:  J J Holland; J C de la Torre; D K Clarke; E Duarte
Journal:  J Virol       Date:  1991-06       Impact factor: 5.103

5.  An assembly defect as a result of an attenuating mutation in the capsid proteins of the poliovirus type 3 vaccine strain.

Authors:  A J Macadam; G Ferguson; C Arnold; P D Minor
Journal:  J Virol       Date:  1991-10       Impact factor: 5.103

6.  Correlation between amount of virus with altered nucleotide sequence and the monkey test for acceptability of oral poliovirus vaccine.

Authors:  K M Chumakov; L B Powers; K E Noonan; I B Roninson; I S Levenbook
Journal:  Proc Natl Acad Sci U S A       Date:  1991-01-01       Impact factor: 11.205

7.  Identification of a consistent pattern of mutations in neurovirulent variants derived from the sabin vaccine strain of poliovirus type 2.

Authors:  M Equestre; D Genovese; F Cavalieri; L Fiore; R Santoro; R Perez Bercoff
Journal:  J Virol       Date:  1991-05       Impact factor: 5.103

8.  Attenuating mutations in glycoproteins E1 and E2 of Sindbis virus produce a highly attenuated strain when combined in vitro.

Authors:  J M Polo; R E Johnston
Journal:  J Virol       Date:  1990-09       Impact factor: 5.103

9.  An attenuating mutation in the 2A protease of swine vesicular disease virus, a picornavirus, regulates cap- and internal ribosome entry site-dependent protein synthesis.

Authors:  Y Sakoda; N Ross-Smith; T Inoue; G J Belsham
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

10.  Identification of two determinants that attenuate vaccine-related type 2 poliovirus.

Authors:  R B Ren; E G Moss; V R Racaniello
Journal:  J Virol       Date:  1991-03       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.